Chlorphenamine (Chlorpheniramine)

Overview

Chlorpheniramine (Chlor-Trimeton®) is a first-generation antihistamine widely used in veterinary medicine for its antihistaminic and antipruritic effects in dogs and cats. It is most commonly used as part of the management of allergic diseases, particularly as an adjunctive therapy in atopic dermatitis and other hypersensitivity disorders.

Compared with newer antihistamines, chlorpheniramine has moderate sedative properties due to its ability to cross the blood–brain barrier. In addition to reducing allergic responses, it may also produce mild tranquilizing and antiemetic effects. Clinical response to antihistamines in animals is variable, and therapeutic trials are often required to determine effectiveness.

Mechanism of Action (MOA): Chlorpheniramine is a competitive antagonist of histamine H1 receptors. By blocking H1 receptor activity, it prevents histamine from exerting its effects on target tissues during allergic reactions. Besides its antihistaminic activity, chlorpheniramine also exhibits varying degrees of anticholinergic, sedative, antispasmodic, mild bronchodilator, and local anesthetic effects.

Pharmacokinetic data in small animals are limited. In dogs, oral bioavailability is reported to range from approximately 10% to 40%, with rapid distribution to extravascular tissues and an elimination half-life of about 1.7 hours. The drug undergoes hepatic metabolism and is primarily excreted in the urine.

Indications

Chlorpheniramine is used in dogs and cats primarily for its antihistaminic and antipruritic effects. It is most commonly administered as part of the management of allergic and hypersensitivity disorders and may also be used as supportive therapy in certain acute reactions.

• Allergic disease: Used to help control clinical signs associated with allergic dermatitis, atopic dermatitis, insect bite hypersensitivity, and other histamine-mediated allergic conditions.
• Antipruritic therapy: Frequently used to reduce pruritus associated with allergic skin disease, often as part of a multimodal management plan.
• Anaphylaxis (adjunctive treatment): May be administered as supportive therapy during prevention or early management of anaphylactic reactions after primary stabilization.
• Premedication before transfusions or chemotherapy: Commonly used to reduce the risk of allergic reactions associated with blood transfusions or administration of certain chemotherapeutic drugs.

Dosage (Reference)

Dog

In dogs, chlorpheniramine is used primarily as an antihistamine for management of allergic conditions and pruritus. Dosing is generally based on a fixed dose per dog rather than body weight, and the response to antihistamines may vary between individual patients.

Cat

In cats, chlorpheniramine is commonly used as an oral antihistamine for allergic skin disease and pruritus. Individual responses vary, and some cats may experience either sedation or paradoxical excitement.

Warnings & Precautions

Chlorpheniramine is generally well tolerated in dogs and cats when used at recommended doses, but its anticholinergic and sedative properties require careful patient selection. Certain underlying medical conditions may increase the risk of adverse effects.

• Hypersensitivity: Contraindicated in animals with known hypersensitivity to chlorpheniramine or other antihistamines of the same class.
• Anticholinergic effects: Because chlorpheniramine has anticholinergic activity, it should be used cautiously in patients with narrow-angle glaucoma, prostatic hypertrophy, urinary retention, or gastrointestinal obstruction such as pyloroduodenal or bladder neck obstruction.
• Cardiovascular and endocrine disease: Use cautiously in animals with cardiovascular disease, hypertension, or hyperthyroidism, as antihistamines may worsen clinical instability in susceptible patients.
• Renal dysfunction: Use with caution in animals with renal impairment because drug elimination may be prolonged.
• Respiratory conditions: Anticholinergic activity may reduce mucosal secretions, therefore caution is advised in animals with pulmonary diseases characterized by minimal airway secretions.
• Use in cats: Palatability can be problematic due to the bitter taste of the medication, which may make oral administration difficult.
• Drug identification errors: Care should be taken not to confuse chlorpheniramine with similarly named drugs such as clomipramine or chlorpromazine.
• Pregnancy and lactation: Although experimental studies in laboratory animals have not shown reproductive harm at high doses, safety in dogs and cats has not been fully established. The drug should be used during pregnancy or lactation only when the potential benefits outweigh possible risks to the offspring.

Drug Interactions

Clinically relevant interactions with chlorpheniramine are primarily related to additive central nervous system depression, enhanced anticholinergic effects, or interference with drugs affecting gastrointestinal motility or cholinergic transmission. Careful monitoring and dose adjustment may be necessary when chlorpheniramine is used concurrently with the following medications.

• Acetylcholinesterase inhibitors (e.g., neostigmine, pyridostigmine): Chlorpheniramine may reduce the therapeutic effects of acetylcholinesterase inhibitors.
• Anticholinergic agents (e.g., atropine, glycopyrrolate, oxybutynin): Concurrent administration may result in additive anticholinergic effects such as dry mouth, urinary retention, and decreased gastrointestinal motility.
• Anticoagulants (e.g., heparin, warfarin): Chlorpheniramine may partially counteract the anticoagulant effects of these drugs.
• Other CNS depressants (e.g., acepromazine, ketamine, methocarbamol, mirtazapine, phenobarbital, trazodone): Additive CNS depression and sedation may occur when combined with chlorpheniramine.
• Monoamine oxidase inhibitors (MAOIs; e.g., amitraz, amitriptyline, selegiline): May prolong and intensify the anticholinergic effects of chlorpheniramine.
• Opioids (e.g., buprenorphine, fentanyl, hydromorphone, methadone, morphine, tramadol): Concurrent use may increase sedation and anticholinergic effects.
• Oral potassium supplements: Agents that decrease gastrointestinal motility may increase the risk of upper GI injury from solid potassium salt formulations.
• Prokinetic agents (e.g., cisapride, metoclopramide): Chlorpheniramine may reduce the therapeutic effects of prokinetic drugs.
• Tricyclic antidepressants (e.g., amitriptyline, clomipramine): Additive CNS depression and anticholinergic effects may occur with concurrent administration.

Side Effects & Overdose

Side Effects

Adverse effects associated with chlorpheniramine are generally mild and dose-dependent. Most reactions are related to its sedative and anticholinergic properties. Individual responses vary between animals, and some effects may decrease with continued administration.

• CNS depression: Lethargy and sedation are the most commonly reported effects, particularly at the beginning of therapy.
• Gastrointestinal effects: Constipation, diarrhea, vomiting, and decreased appetite may occur.
• Anticholinergic effects: Dry mouth, decreased gastrointestinal motility, and urinary retention may develop in some patients.
• Paradoxical excitation: Some animals, particularly cats, may develop agitation or excitement rather than sedation.
• Working dogs: Sedative effects may interfere with the performance of working or service animals.
• Tolerance to sedation: With continued administration, sedative effects may diminish over time in some patients.

Overdose

Overdose of first-generation antihistamines such as chlorpheniramine can cause significant neurologic and anticholinergic toxicity. Clinical signs may include either central nervous system stimulation or depression, depending on the dose and patient sensitivity.

• CNS effects: Hyperexcitability, tremors, seizures, or severe depression leading to stupor or coma.
• Anticholinergic toxicity: Dry mucous membranes, decreased gastrointestinal motility, urinary retention, and tachycardia may occur.
• Respiratory depression: Severe intoxication may impair respiratory function.
• Cardiovascular complications: Bradycardia, arrhythmias, and cardiovascular collapse may develop in severe cases.
• Severe toxicity: High doses have been associated with neurologic dysfunction, coma, and death in dogs.
• Management: Treatment is primarily supportive and may include gastrointestinal decontamination (emesis if appropriate), administration of activated charcoal, and symptomatic supportive care based on clinical signs.

Key Notes

Practical clinical considerations that may help optimize the use of chlorpheniramine in dogs and cats during routine veterinary practice:

• Variable clinical response: Antihistamines do not work equally in all patients. A short therapeutic trial is often needed to determine whether chlorpheniramine is effective for a particular animal.
• Regular administration improves efficacy: Antihistamines tend to work better when given consistently and started before exposure to known allergens rather than after clinical signs become severe.
• Use as part of multimodal allergy management: Chlorpheniramine is commonly combined with other therapies (e.g., fatty acids, corticosteroids, immunotherapy, or antipruritic agents) in long-term management of allergic skin disease.
• Clinical monitoring during trials: Treatment trials for antihistamines typically last about 1–2 weeks to evaluate whether pruritus or allergic signs improve.
• OTC product caution: Many human over-the-counter antihistamine products contain additional ingredients such as decongestants or analgesics that may be toxic to animals; only products containing chlorpheniramine alone should be used.
• Formulation considerations: Extended-release tablets should not be split or crushed, as this may alter drug release and absorption.
• Allergy testing considerations: Antihistamines can suppress results of intradermal allergy testing; chlorpheniramine should ideally be discontinued several days before testing.